What's new in antibiotic resistance? Focus on beta-lactamases

被引:160
作者
Babic, Maja
Hujer, Andrea M.
Bonomo, Robert A.
机构
[1] Case Western Reserve Univ, Vet Affairs Med Ctr, Infect Dis Sect, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA
关键词
beta-lactamases; cephalosporinases; carbapenemases; extended-spectrum beta-lactamases; ESBLs;
D O I
10.1016/j.drup.2006.05.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In gram-negative bacteria, beta-lactamases are the most important mechanism of resistance to beta-lactam antibiotics. Currently, the beta-lactamases receiving the most attention are the extended-spectrum beta-lactamases (ESBLs), inhibitor-resistant beta-lactamases and carbapenemases. When found in Escherichia coli and Klebsiella spp., ESBLs confer resistance to extended-spectrum cephalosporins, such as ceftazidime, cefotaxime and cefepime. Hence, ESBLs limit the choice of beta-lactam therapy to carbapenems. A worrisome trend is the increasing number of pathogens found in isolates from patients in the community that possess ESBLs. It is equally distressing that carbapenemases (serine and metallo-beta-lactamases) are being found in many of the same bacteria that harbor ESBLs, for example Klebsiella pneumoniae. Despite many years studying beta-lactamases, important clinical and scientific questions still remain. Published by Elsevier Ltd.
引用
收藏
页码:142 / 156
页数:15
相关论文
共 140 条
[1]   Kinetics study of KPC-3, a plasmid-encoded class a carbapenem-hydrolyzing β-lactamase [J].
Alba, J ;
Ishii, Y ;
Thomson, K ;
Moland, ES ;
Yamaguchi, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4760-4762
[3]   SHV-16, a β-lactamase with a pentapeptide duplication in the omega loop [J].
Arpin, C ;
Labia, R ;
Andre, C ;
Frigo, CC ;
El Harrif, Z ;
Quentin, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2480-2485
[4]   Role of the 'cre/blr-tag' DNA sequence in regulation of gene expression by the Aeromonas hydrophila β-lactamase regulator, BlrA [J].
Avison, MB ;
Niumsup, P ;
Nurmahomed, K ;
Walsh, TR ;
Bennett, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) :197-202
[5]   CHARACTERIZATION OF A NEW TEM-TYPE BETA-LACTAMASE RESISTANT TO CLAVULANATE, SULBACTAM, AND TAZOBACTAM IN A CLINICAL ISOLATE OF ESCHERICHIA-COLI [J].
BLAZQUEZ, J ;
BAQUERO, MR ;
CANTON, R ;
ALOS, I ;
BAQUERO, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2059-2063
[6]   Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin [J].
Bogdanovich, T ;
Ednie, LM ;
Shapiro, S ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4210-4219
[7]   Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes [J].
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :1-14
[8]   The antimicrobial armamentarium: Evaluating current and future treatment options [J].
Bosso, JA .
PHARMACOTHERAPY, 2005, 25 (10) :55S-62S
[9]   Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].
Bradford, PA ;
Bratu, S ;
Urban, C ;
Visalli, M ;
Mariano, N ;
Landman, D ;
Rahal, JJ ;
Brooks, S ;
Cebular, S ;
Quale, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60
[10]   Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:: molecular epidemiology and in vitro activity of polymyxin B and other agents [J].
Bratu, S ;
Tolaney, P ;
Karumudi, U ;
Quale, J ;
Mooty, M ;
Nichani, S ;
Landman, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :128-132